BACKGROUND: Myocardial extracellular matrix remodelling provides electrical heterogeneity entailing ventricular tachycardia/fibrillation (VT/VF) in heart failure (HF) patients. Osteopontin (OPN) and Galectin-3 (Gal-3) are fibrosis markers and may reflect the extension of the arrhythmogenic substrate. We assessed whether plasma OPN and Gal-3 predict the risk of sustained VT/VF in a cohort of HF patients with implantable cardioverter-defibrillator (ICD). METHODS: A total of 75 HF patients underwent pre-ICD implantation clinical evaluation and assessment of plasma OPN and Gal-3. The primary endpoint was the time to the occurrence of the first sustained VT/VF. Hazard ratios (HR) were derived from Cox proportional-hazards analysis. RESULTS: Patients with coronary artery disease (CAD) had higher plasma OPN (79.8 ± 44.0 ng/mL vs. 66.0 ± 31.8 ng/mL; P = 0.04). Both Gal-3 (r = -0.38; P = 0.01) and OPN (r = -0.27; p = 0.01) were negatively related to estimated glomerular filtration rate. After 29 ± 17 months, 20 patients (27%) reached the primary endpoint. Patients with VT/VF had higher plasma OPN and Gal-3 (97.4 ± 51.7 ng/mL vs. 65.9 ± 31.3 ng/mL; P = 0.002 and 19.7 ± 8.5 ng/mL vs. 16.2 ± 6.2 ng/mL; P = 0.05). In univariate analysis, OPN (log-OPN, HR: 32.4; 95%CI: 3.9-264.7; P = 0.001) and Gal-3 (HR: 1.05; 95%CI: 1.00-1.11; P = 0.04) predicted sustained VT/VF. In multivariable analysis, both OPN (HR: 41.4; 95%CI: 3.8-441.9; P = 0.002) and Gal-3 (HR: 1.06; 95%CI: 1.00-1.12; P = 0.03) retained their prognostic power after correction for age, sex, history of MI, EF, NYHA class, eGFR, use of ACE-I, and amiodarone. CONCLUSIONS: Plasma OPN and Gal-3 predict sustained VT/VF in HF patients at high risk for SCD. Larger prospective studies should outline the role of these biomarkers in predicting SCD on top of conventional risk stratification.
BACKGROUND: Myocardial extracellular matrix remodelling provides electrical heterogeneity entailing ventricular tachycardia/fibrillation (VT/VF) in heart failure (HF) patients. Osteopontin (OPN) and Galectin-3 (Gal-3) are fibrosis markers and may reflect the extension of the arrhythmogenic substrate. We assessed whether plasma OPN and Gal-3 predict the risk of sustained VT/VF in a cohort of HF patients with implantable cardioverter-defibrillator (ICD). METHODS: A total of 75 HF patients underwent pre-ICD implantation clinical evaluation and assessment of plasma OPN and Gal-3. The primary endpoint was the time to the occurrence of the first sustained VT/VF. Hazard ratios (HR) were derived from Cox proportional-hazards analysis. RESULTS:Patients with coronary artery disease (CAD) had higher plasma OPN (79.8 ± 44.0 ng/mL vs. 66.0 ± 31.8 ng/mL; P = 0.04). Both Gal-3 (r = -0.38; P = 0.01) and OPN (r = -0.27; p = 0.01) were negatively related to estimated glomerular filtration rate. After 29 ± 17 months, 20 patients (27%) reached the primary endpoint. Patients with VT/VF had higher plasma OPN and Gal-3 (97.4 ± 51.7 ng/mL vs. 65.9 ± 31.3 ng/mL; P = 0.002 and 19.7 ± 8.5 ng/mL vs. 16.2 ± 6.2 ng/mL; P = 0.05). In univariate analysis, OPN (log-OPN, HR: 32.4; 95%CI: 3.9-264.7; P = 0.001) and Gal-3 (HR: 1.05; 95%CI: 1.00-1.11; P = 0.04) predicted sustained VT/VF. In multivariable analysis, both OPN (HR: 41.4; 95%CI: 3.8-441.9; P = 0.002) and Gal-3 (HR: 1.06; 95%CI: 1.00-1.12; P = 0.03) retained their prognostic power after correction for age, sex, history of MI, EF, NYHA class, eGFR, use of ACE-I, and amiodarone. CONCLUSIONS: Plasma OPN and Gal-3 predict sustained VT/VF in HF patients at high risk for SCD. Larger prospective studies should outline the role of these biomarkers in predicting SCD on top of conventional risk stratification.
Authors: My-Nhan Nguyen; Yidan Su; Donna Vizi; Lu Fang; Andris H Ellims; Wei-Bo Zhao; Helen Kiriazis; Xiao-Ming Gao; Junichi Sadoshima; Andrew J Taylor; Julie R McMullen; Anthony M Dart; David M Kaye; Xiao-Jun Du Journal: Sci Rep Date: 2018-05-29 Impact factor: 4.379
Authors: Mausam Patel; Daniela Rodriguez; Keyvan Yousefi; Krista John-Williams; Armando J Mendez; Ronald B Goldberg; Anastasios Lymperopoulos; Leonardo J Tamariz; Jeffrey J Goldberger; Robert J Myerburg; Juhani Junttila; Lina A Shehadeh Journal: Front Cardiovasc Med Date: 2020-11-30
Authors: Stephan R Künzel; Maximilian Hoffmann; Michael Wagner; Ali El-Armouche; Silvio Weber; Karolina Künzel; Susanne Kämmerer; Mario Günscht; Erik Klapproth; Johanna S E Rausch; Mirna S Sadek; Tomasz Kolanowski; Stefanie Meyer-Roxlau; Christopher Piorkowski; Sems M Tugtekin; Stefan Rose-John; Xiaoke Yin; Manuel Mayr; Jan Dominik Kuhlmann; Pauline Wimberger; Konrad Grützmann; Natalie Herzog; Jan-Heiner Küpper; Molly O'Reilly; S Nashitha Kabir; Laura C Sommerfeld; Kaomei Guan; Ben Wielockx; Larissa Fabritz; Stanley Nattel; Ursula Ravens; Dobromir Dobrev Journal: Circ Res Date: 2021-08-26 Impact factor: 17.367
Authors: Hisaki Makimoto; Patrick Müller; Kullmann Denise; Lukas Clasen; Tina Lin; Stephan Angendohr; Jan Schmidt; Christoph Brinkmeyer; Malte Kelm; Alexandru Bejinariu Journal: Intern Med Date: 2022-04-01 Impact factor: 1.271